Assessment and Management of BV, Chlamydia, and Trichomoniasis
Assessment
Obtain vaginal pH, perform wet mount microscopy, and collect specimens for NAAT testing for chlamydia and trichomoniasis—these are your essential diagnostic tools. 1
Bacterial Vaginosis (BV)
- Diagnostic criteria (Amsel's): Need 3 of 4 findings:
- Thin, homogeneous white-gray discharge
- Vaginal pH >4.5
- Positive whiff test (fishy odor with KOH)
- Clue cells on wet mount 2
- Alternative: Gram stain with Nugent scoring system (laboratory-based) 2
- Microscopy sensitivity is approximately 60-70% 1
Trichomoniasis
- Wet mount microscopy: Only 60-70% sensitive 1
- Preferred: NAAT from vaginal or urine specimen (most sensitive) 1
- Alternative: Point-of-care antigen testing or culture 1
- Clinical features: Diffuse, malodorous yellow-green discharge with vulvar irritation, though many women have minimal symptoms 1
Chlamydia
- NAAT testing from vaginal, cervical, or urine specimens (preferred method) 1, 3
- Most infections are asymptomatic in both men and women 1
- Screen all sexually active women ≤25 years annually, plus older women with risk factors (new/multiple partners) 1
Treatment Plans
Bacterial Vaginosis
Treat all symptomatic women with oral metronidazole 500 mg twice daily for 7 days. 1, 2
Recommended regimens:
- Metronidazole 500 mg PO BID × 7 days (first-line) 1
- Metronidazole gel 0.75%, one applicator intravaginally daily × 5 days 1
- Clindamycin cream 2%, one applicator intravaginally at bedtime × 7 days 1
Alternative regimens (lower efficacy):
Critical counseling points:
- Avoid alcohol during metronidazole therapy and for 24 hours after completion 1
- Oil-based clindamycin products weaken latex condoms and diaphragms 1
Pregnancy considerations:
- Same regimens as non-pregnant women 1
- Screen and treat high-risk pregnant women (prior preterm delivery) at first prenatal visit to reduce preterm birth risk 1
- Follow-up at 1 month post-treatment in high-risk pregnant women 1
Trichomoniasis
Prescribe metronidazole 2 g orally as a single dose and treat all sexual partners simultaneously. 1
Recommended regimen:
- Metronidazole 2 g PO single dose 1
Alternative regimen:
- Metronidazole 500 mg PO BID × 7 days 1
Both regimens achieve 90-95% cure rates 1
Treatment failures:
- First failure: Re-treat with metronidazole 500 mg BID × 7 days 1
- Second failure: Metronidazole 2 g PO daily × 3-5 days 1
- Persistent failure: Consult specialist for susceptibility testing (contact CDC) 1
Partner management:
- Treat all partners (even without testing) to prevent reinfection 1
- Abstain from sex until both patient and partner complete therapy and are asymptomatic 1
Pregnancy:
- Treat symptomatic pregnant women with metronidazole 2 g single dose (safe after first trimester, though older guidelines contraindicated first trimester use) 1, 2
- Treatment reduces preterm birth risk 2
Critical pitfall: Metronidazole gel is NOT effective for trichomoniasis (<50% cure rate)—only use oral formulations 1
Chlamydia
Administer azithromycin 1 g orally as a single observed dose, or prescribe doxycycline 100 mg twice daily for 7 days. 4, 1
Recommended regimens (equally efficacious):
Alternative regimens:
- Erythromycin base 500 mg PO QID × 7 days 4, 1
- Erythromycin ethylsuccinate 800 mg PO QID × 7 days 4, 1
- Ofloxacin 300 mg PO BID × 7 days 4, 1
- Levofloxacin 500 mg PO daily × 7 days 1
Practical considerations:
- Azithromycin preferred when compliance is questionable—enables directly observed therapy 4, 1
- Doxycycline is less expensive with longer track record 1
- Dispense medications on-site and observe first dose 4, 1
Partner management:
- Treat all partners from past 60 days 4
- Abstain from sex for 7 days after single-dose therapy or until completion of 7-day regimen 4, 1
Coinfection consideration:
Follow-up:
- Test of cure not routinely needed if asymptomatic 4, 1
- No follow-up required for compliant patients who become asymptomatic 4
Key Clinical Pearls
HIV-positive patients: Use identical treatment regimens as HIV-negative patients for all three conditions 4, 1
Sexual assault survivors: Provide presumptive treatment for chlamydia, gonorrhea, and trichomoniasis due to poor follow-up compliance 3
Common diagnostic error: Relying solely on clinical symptoms—they overlap significantly between conditions and require laboratory confirmation 5
Recurrent BV: Consider longer treatment courses (extended duration with first-line agents) 6, 2